Torasemide

DRUG3 trials

Sponsors

Boehringer Ingelheim, Medical University of Warsaw, Ospedale San Raffaele

Conditions

Diabetes Mellitus, Type 2Drug EffectGenetic PredispositionHeart FailureHypertension

Phase 1

Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes

CompletedNCT01276288

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2011-01-31Updated: 2014-09-03

Phase 3

Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment

CompletedNCT06413082

Ospedale San RaffaeleDrug Effect, Genetic Predisposition, Hypertension

Start: 2021-02-15End: 2023-09-03Updated: 2024-05-16

Phase 4

The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure

Medical University of WarsawHeart Failure

Start: 2013-09-30End: 2018-12-31Target: 100Updated: 2017-06-08

Related Papers

Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial.

2019-01-0115 citations

The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.

2017-01-231 citations

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.

2016-09-2869 citations

Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus.

2016-09-2241 citations

Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.

2015-01-2815 citations